Goa facility FDA classification pending
Goa facility received six 483 observations after U.S. FDA reinspection; official classification awaited, which could impact product approvals.
CIPLA / Q1-FY25 / risks
Keep the risk register visible.
Cipla · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Potential price erosion from new Albuterol entrants
New competitors entering the Albuterol inhalation market could lead to price erosion and market share loss, though management notes market expansion.
Lanreotide supply constraints limiting ramp-up
Supply from partner is constrained, leading to gradual ramp-up for Lanreotide generic; capacity limitations may cap near-term revenue.
Trade generic transition disruption
Transition to new distribution model caused temporary softness in trade generic business; recovery expected but execution risk remains.